Newbridge Financial Services Group’s Cardiff Oncology CRDF Stock Holding History

Newbridge Financial Services Group’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-17	Closed	-$91	–	1120
2024 Q1	$91	Hold	17	–	–	﹤0.01%	1145
2023 Q4	$25	Sell	17 -98	-85%	-$119	﹤0.01%	1107
2023 Q3	$160	Hold	115	–	–	﹤0.01%	1242
2023 Q2	$169	Hold	115	–	–	﹤0.01%	1293
2023 Q1	$190	Hold	115	–	–	﹤0.01%	1351
2022 Q4	$161	Hold	115	–	–	﹤0.01%	1391
2022 Q3	$0	Sell	115 -716	-86%	-$1.72K	﹤0.01%	1398
2022 Q2	$2K	Hold	831	–	–	﹤0.01%	1163
2022 Q1	$2K	Hold	831	–	–	﹤0.01%	1277
2021 Q4	$5K	Hold	831	–	–	﹤0.01%	1060
2021 Q3	$6K	Buy	831 +733	+748%	+$4.61K	﹤0.01%	968
2021 Q2	$1K	Hold	98	–	–	﹤0.01%	1340
2021 Q1	$1K	Buy	+98	New	+$1.19K	﹤0.01%	1249

Other funds holding CRDF

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BIT Capital Berlin, Germany $3.38B AUM 214.12% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Newbridge Financial Services Group's CRDF Position: Q2 2024 in Review

Newbridge Financial Services Group sold out of Cardiff Oncology (CRDF) in Q2 2024, closing a stake of 17 shares — an estimated $91 sold.

Newbridge Financial Services Group first reported a position in CRDF in Q1 2021 and held it in 13 quarters. The position peaked at $6K in Q3 2021. 90 funds tracked by Wall St. Rank hold CRDF as of Q2 2024.

Newbridge Financial Services Group reported no remaining Cardiff Oncology position as of Q2 2024 after selling out during the quarter.
Newbridge Financial Services Group sold 17 Cardiff Oncology shares in Q2 2024, an estimated $91.
Newbridge Financial Services Group first reported a position in Cardiff Oncology in Q1 2021 and held it in 13 quarters.
Newbridge Financial Services Group's Cardiff Oncology position peaked at $6K in Q3 2021.
90 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2024.

Based on Newbridge Financial Services Group's 13F filing for Q2 2024, filed 11 Sep 2024.